CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Podobne knjige/članki

• Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
  od: Van Assche, G, et al.
  Izdano: (2006)
• Fontolizumab, a humanised anti‐interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
  od: Hommes, D W, et al.
  Izdano: (2006)
• A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti‐interferon γ antibody, in patients with moderate to severe Crohn's disease
  od: Reinisch, W, et al.
  Izdano: (2006)
• Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
  od: Panés, Julian, et al.
  Izdano: (2017)
• A phase II study of laquinimod in Crohn's disease
  od: D'Haens, Geert, et al.
  Izdano: (2015)